Welcome to our dedicated page for Astria Therapeutics SEC filings (Ticker: ATXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Astria Therapeutics, Inc. (ATXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq‑listed biopharmaceutical issuer. Astria’s filings, including Forms 8‑K, 10‑K, and 10‑Q when available, document key information about its clinical‑stage programs in hereditary angioedema and atopic dermatitis, as well as its material agreements and corporate transactions.
Recent Form 8‑K filings illustrate how Astria uses SEC reports to communicate significant events. One 8‑K describes an Agreement and Plan of Merger with BioCryst Pharmaceuticals, Inc., under which a BioCryst subsidiary will merge with and into Astria, with Astria surviving as a wholly owned subsidiary if closing conditions are met. The filing outlines the cash and stock consideration, treatment of common stock, preferred stock, options, and warrants, and notes that Astria common stock is expected to be delisted from Nasdaq and deregistered under the Exchange Act if the merger is consummated.
Another 8‑K details a license agreement with Kaken Pharmaceutical Co., Ltd., granting Kaken exclusive rights to develop, package, and commercialize navenibart in Japan for prevention of hereditary angioedema attacks, including financial terms such as an upfront payment, potential milestones, and tiered royalties, as well as Kaken’s obligations to support Phase 3 development and handle regulatory submissions in Japan. Additional 8‑K filings cover quarterly financial results and other corporate updates.
On Stock Titan, these SEC filings are paired with AI‑powered summaries that explain the core points of lengthy documents, helping readers quickly understand merger terms, licensing economics, clinical development commitments, and capital considerations. Real‑time updates from EDGAR ensure new Astria filings, including future 10‑K annual reports, 10‑Q quarterly reports, and any Form 4 insider transaction reports, are surfaced promptly, while AI‑generated highlights make dense regulatory language more accessible for investors researching ATXS.
Vestal Point Capital and Ryan Wilder report owning 0 shares, or 0%, of Astria Therapeutics common stock as of December 31, 2025. They previously filed as significant holders but now certify beneficial ownership of 5 percent or less of the class.
The filing is made on Schedule 13G/A, with the reporting persons describing themselves as an investment adviser and an individual control person, and stating that any securities were acquired and held in the ordinary course of business, not to change or influence control of Astria Therapeutics.
Glazer Capital, LLC and Paul J. Glazer report beneficial ownership of 3,776,154 shares of Astria Therapeutics, Inc. common stock, equal to 6.61% of the outstanding class as of 12/31/2025.
All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported. The filers certify that the securities were acquired and are held as a passive investment, not for the purpose of changing or influencing control of Astria Therapeutics.
Astria Therapeutics, Inc. filed an amended Schedule 13D showing that investment entities affiliated with Perceptive Advisors no longer own any of its common stock. The filing reports that Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd., and Perceptive Xontogeny Venture Fund, L.P. each hold 0 shares and 0% of the class.
This change follows the previously announced acquisition of Astria by BioCryst under a merger agreement. The merger was completed on January 23, 2026, and Astria ceased to exist as a separate entity, which eliminated the reporting persons’ beneficial ownership in the company’s shares.
Astria Therapeutics, Inc. completed a cash merger in which each share of its Class A common stock was converted into the right to receive $8.55 in cash, without interest, as of the closing on January 23, 2026.
Funds and accounts managed by Magnetar-affiliated entities previously held 3,431,007 shares, which were cancelled and converted into this cash consideration. The filing states that, following the merger, Magnetar Financial LLC, Magnetar Capital Partners, Supernova Management LLC, and David J. Snyderman each report beneficial ownership of 0 shares, or 0% of the class.
The amendment also notes that since their October 24, 2025 report, the reporting persons purchased an additional 118,805 shares for an aggregate of $1,501,294.83 on behalf of the funds before all holdings were cashed out in the merger.